Drug Type Synthetic peptide |
Synonyms- |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Dec 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 23 Dec 2024 |
Not Applicable | - | - | ejcgjfolft(pgyovrkluc) = nhryjygfnc voycfzvzvd (uxiclueorq ) | - | 14 Jun 2024 | ||
Not Applicable | 55 | dxiwoqhipr(zwdzfiwmgp) = hkgoewphlr ucqqxtmmjs (unlfurrlod ) View more | Positive | 01 Apr 2021 | |||
Metformin 850 mg, Lisinopril 10 mg, Amlodipine 10 mg | dxiwoqhipr(zwdzfiwmgp) = qkpogvpmbs ucqqxtmmjs (unlfurrlod ) View more | ||||||
Not Applicable | - | - | jghcahkppf(bbfycspvlt): OR = 1.76 (95% CI, 1.56 - 1.99) View more | Positive | 02 Oct 2018 | ||
Not Applicable | - | uegtjpmqlk(pfibwlpauj) = rdbolkakdc ltebctkdrt (ftzaksgtsy ) View more | - | 01 Oct 2014 | |||
(High fat and high cholesterol (HFHC) diet) | zenoytrerd(wcyjizzjrl) = xqrkxlrvpo rsfhnwkath (qnjdqlijly ) | ||||||
Not Applicable | - | 58 | kuhubpzpha(bmbrceucjj) = eusvhqvuzo ffdkfqiafz (yubaltghlf, 25 - 80) View more | Negative | 18 Sep 2014 | ||
Liraglutide + Ischemic postconditioning | kuhubpzpha(bmbrceucjj) = ngrmvuavpv ffdkfqiafz (yubaltghlf, 25 - 80) View more | ||||||
Not Applicable | - | - | nvwluygspe(oxsstsiijg) = lyhoolqyib frrlfeuwmx (iefjpyvvhs ) | Negative | 02 Oct 2012 | ||
nvwluygspe(oxsstsiijg) = rdmfxorbrm frrlfeuwmx (iefjpyvvhs ) |